Huntington's disease (HD) is a progressive neurodegenerative disorder, of which the pathogenesis is not completely understood. In patients with Huntington's disease, there is a mutation in the gene encoding the protein huntingtin, which results in an expanded polyglutamine sequence leading to degeneration of the basal ganglia. There is mounting evidence that metabolism of the transmitter dopamine by the enzyme monoamine oxidase may contribute to striatal damage in mitochondrial toxin-induced models of HD. In this study, we have examined the role of the catecholamine tyramine in neural SH-SY5Y cells transfected with normal and expanded polyglutamine repeat numbers. Our findings demonstrate that cells containing a pathological number of polyglutamines are more sensitive to tyramine than cells with a non-pathological number. Tyramine-induced cell death was attenuated by MAO inhibitors as well as with catalase and the iron chelator deferoxamine, suggesting that H202 might mediate the observed toxicity. These observations support the notion that the metabolism of dopamine plays a role in neuron death in Huntington's disease.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11064-005-2687-zDOI Listing

Publication Analysis

Top Keywords

huntington's disease
12
catecholamine tyramine
8
sh-sy5y cells
8
expanded polyglutamine
8
enhanced toxicity
4
toxicity catecholamine
4
tyramine polyglutamine
4
polyglutamine transfected
4
transfected sh-sy5y
4
cells
4

Similar Publications

Rare diseases may affect the quality of life of patients and be life-threatening. Therapeutic opportunities are often limited, in part because of the lack of understanding of the molecular mechanisms underlying these diseases. This can be ascribed to the low prevalence of rare diseases and therefore the lower sample sizes available for research.

View Article and Find Full Text PDF

Background: Stroop task is used to evaluate inhibition, a core executive function. Alpha Event-Related Desynchronization (ERD) from analysis of electroencephalogram (EEG) during Stroop task reflects brain interference processing. We previously reported different relationships between heart rate variability (HRV) and alpha ERD during Stroop task.

View Article and Find Full Text PDF

Background: At the pre-clinical stages of Alzheimer's disease (AD) development, the accumulation of amyloid-β (Aβ) and tau induces neural toxicity, synaptic dysfunction, and excitation/inhibition instability of neural network activity, leading to cognitive decline. However, the effects of Aβ/tau accumulation on electroencephalography (EEG) functional connectivity (FC) in cognitively healthy (CH) individuals during a cognitive challenge have not been elucidated. Therefore, the main objective of this work is to evaluate the association between Aβ/tau level and brain FC during a cognitive challenge in CH individuals.

View Article and Find Full Text PDF

Background: Parkinson's (PD) is common and debilitating with over half of patients progressing to postural instability, dementia or death within 10 years. However, onset and rate of progression is highly variable, reflecting heterogeneity in underlying pathology, and biomarker studies to-date have been limited to a single modality or assessed patients with established cognitive impairment.

Method: We assessed multimodal neuroimaging and plasma biomarkers in 98 PD patients (mean disease duration at baseline 4.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Stanford University School of Medicine, Stanford, CA, USA.

The ability to define neurodegenerative diseases of aging based of biology rather than clinically defined syndromic presentations follows from biomarker development and reflects underlying pathology in living people. The NIA-AA Research Framework (Jack et al 2018 Alzheimers Dement) proposed the biological definition for Alzheimer's disease (AD) and sought to provide a common language to identify and stage research participants, who were not cognitively impaired but had abnormal AD biomarkers; it has been revised. The biological classification of Huntington's disease (Tabrizi et al 2022 Lancet Neurology) included a biological research definition with an integrated staging system, centered on biological, clinical, and functional assessments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!